US organ transplant tech firm's Q2 revenue rose 21%, beating analyst expectations
Adjusted EPS for Q2 was $0.44; no analyst consensus for comparison
Company raised low end of 2026 revenue guidance and invested in PAD Aviation for EU logistics
Key details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
$189.90 mln
$183.64 mln (11 Analysts)
Q2 EPS
$0.41
Q2 Net Income
$14.70 mln
Q2 Gross Margin
60.00%
Analyst coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", 5 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"
Wall Street's median 12-month price target for Transmedics Group Inc is $120.00, about 47.1% above its August 3 closing price of $81.55
The stock recently traded at 32 times the next 12-month earnings vs. a P/E of 35 three months ago
TMDX•
